Technical Reports on Drug Makers Equities -- Impax Labs, GlaxoSmithKline, Novartis, and TherapeuticsMD

NEW YORK, August 29, 2017 /PRNewswire/ --

If you want a Stock Review on IPXL, GSK, NVS, or TXMD then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. The Drug Manufacturers space includes companies that develop and sell medicines and vaccines for a wide range of medical uses. Most drug manufacturers are structured as corporations, and many offer slightly higher-than-average dividend yields. In today's pre-market research, DailyStockTracker.com dedicates its attention to four major industry players, particularly: Impax Laboratories Inc. (NASDAQ: IPXL), GlaxoSmithKline PLC (NYSE: GSK), Novartis AG (NYSE: NVS), and TherapeuticsMD Inc. (NYSE MKT: TXMD). Learn more about these stocks by downloading their comprehensive and free reports from DailyStockTracker.com member's area at:

http://dailystocktracker.com/register/

Impax Laboratories 

On Monday, shares in Hayward, California headquartered Impax Laboratories Inc. climbed 1.88%, ending the day at $19.00. The stock recorded a trading volume of 1.06 million shares. The Company's shares have surged 26.67% over the previous three months and 43.40% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 9.66% and 32.53%, respectively. Moreover, shares of Impax Labs, which develops, manufactures, and markets bioequivalent pharmaceutical products, have a Relative Strength Index (RSI) of 59.50.

On July 31^st, 2017, research firm Canaccord Genuity initiated a 'Hold' rating on the Company's stock, with a target price of $19 per share.

On August 09^th, 2017, Impax Labs announced Q2 2017 financial results. In Q2 2017, total revenues were $202.1 million; GAAP net loss was $20.4 million; adjusted net income was $13.1 million; and EBITDA was $16.6 million. Cash and cash equivalents were $171.4 million as of June 30^th, 2017. IPXL complete research report is just a click away at:

http://dailystocktracker.com/registration/?symbol=IPXL

GlaxoSmithKline 

Shares in Brentford, the UK headquartered GlaxoSmithKline PLC ended the day 0.03% lower at $39.46 with a total trading volume of 2.38 million shares. The stock has advanced 2.47% on an YTD basis, and is trading below its 200-day moving average by 3.46%. Shares of the Company, which engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide, have an RSI of 38.80. The complimentary report on GSK can be downloaded at:

http://dailystocktracker.com/registration/?symbol=GSK

Novartis 

At the close of trading on Monday, shares in Basel, Switzerland headquartered Novartis AG finished 0.24% lower at $83.33. A total volume of 1.89 million shares was traded, which was above their three months average volume of 1.59 million shares. The stock has advanced 3.48% over the previous three months and 14.40% on an YTD basis. The Company's shares are trading above their 200-day moving average by 8.14%. Additionally, shares of Novartis, which researches, develops, manufactures, and markets healthcare products worldwide, have an RSI of 44.43. Sign up for your complimentary research report on NVS at:

http://dailystocktracker.com/registration/?symbol=NVS

TherapeuticsMD 

Boca Raton, Florida headquartered TherapeuticsMD Inc.'s shares recorded a trading volume of 1.36 million shares at the end of yesterday's session. The stock closed the day 2.36% higher at $6.07. The Company's shares have advanced 8.01% in the past month, 58.07% in the previous three months, and 5.20% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 9.35% and 6.36%, respectively. Additionally, shares of TherapeuticsMD, which operates as a women's health care product company, have an RSI of 57.21.

On August 03^rd, 2017, TherapeuticsMD announced its financial results for Q2 ended June 30^th, 2017. For the quarter, net revenue from the Company's prescription prenatal vitamin business was approximately $4.3 million; cost of goods sold was approximately $0.7 million; and net loss was approximately $19.7 million. At June 30^th, 2017, cash on hand was approximately $96.5 million. Get free access to your research report on TXMD at:

http://dailystocktracker.com/registration/?symbol=TXMD

--

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

DST has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@dailystocktracker.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY 

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://dailystocktracker.com/disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE dailystocktracker.com